Optic nerve neuropathies – causative factors, methods of diagnostics, current and future possibilities of treatment
DOI:
https://doi.org/10.12775/JEHS.2022.12.04.004Keywords
optic nerve, neuropathy, patophysiology, diagnosis, treatment, alcohol use disorder, toxic, vascular disorderAbstract
Introduction: Optic neuropathies are a broad group of diseases in which the dominant disturbance is damage to the optic nerve, often irreversible. Underlying causes of neuropathy are both genetic and environmental. Despite limited treatment options, much research is currently being done on substances that could improve optic nerve function and alleviate the clinical consequences of optic nerve damage.
Purpose: This article describes current findings in both the optic nerve neuropathy pathophysiology and diagnosis of the disorder, as well as treatment options and future perspectives.
State of knowledge: The pathogenetic cause of neuropathy is mainly demyelination within the neural sheath, often caused by inflammation. It is characterized by progressive loss of vision. The most common genetic cause of optic neuropathy is mitochondrially inherited Leber hereditary optic neuropathy (LHON) and is characterized by mostly sudden and painless loss of visual acuity. Toxic neuropathies are a group of diseases caused by heavy metals, pharmaceuticals, methanol and carbon monoxide. Nutritional neuropathy is mainly related to vitamin B1, B9 and B12 deficiency, and is a rare example of neuropathy that can be curable at the early stage of the disease. Another group of neuropathies is caused by ischemia and can be divided according to the place of the optic nerve affected – AION (anterior ischemic optic neuropathy) and PION (posterior ischemic optic neuropathy).
Conclusions: The therapeutic options in the treatment of optic neuropathy strictly depend on the causative factor. Nutritional deficiencies are treated with appropriate supplementation, so it is vital to truly determine the missing vitamins and elements.
References
Walter M, Gerhard U, Gerlach M, Weijers HG, Boening J, Wiesbeck GA. Cortisol concentrations, stress-coping styles after withdrawal, and long-term abstinence in alcohol dependence. Addict Biol. 2006; 11:157–62.
Lightman S, McDonald WI, Bird AC, et al. Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain 1987; 110 (Pt 2):405.
Roed H, Frederiksen J, Langkilde A, et al. Systemic T-cell activation in acute clinically isolated optic neuritis. J Neuroimmunol 2005; 162:165.
Söderström M, Link H, Xu Z, Fredriksson S. Optic neuritis and multiple sclerosis: anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF. Neurology 1993; 43:1215.
Frederiksen JL, Madsen HO, Ryder LP, et al. HLA typing in acute optic neuritis. Relation to multiple sclerosis and magnetic resonance imaging findings. Arch Neurol 1997; 54:76.
Francis DA, Compston DA, Batchelor JR, McDonald WI. A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry 1987; 50:758.
Morrow MJ, Wingerchuk D. Neuromyelitis Optica. J Neuroophthalmol. 2012; 32:154–166.
Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992; 326:581–588
Korkiamäki P, Kervinen M, Karjalainen K, Majamaa K, Uusimaa J, Remes AM. Prevalence of the primary LHON mutations in Northern Finland associated with bilateral optic atrophy and tobacco-alcohol amblyopia. Acta Ophthalmol. 2013 Nov;91(7):630-4. doi: 10.1111/j.1755-3768.2012.02506.x. Epub 2012 Sep 12. PMID: 22970697.
Spruijt L, Kolbach DN, de Coo RF, Plomp AS, Bauer NJ, Smeets HJ, de Die-Smulders CE. Influence of mutation type on clinical expression of Leber hereditary optic neuropathy. Am J Ophthalmol. 2006 Apr;141(4):676-82. doi: 10.1016/j.ajo.2005.11.007. PMID: 16564802.
Spruijt L, Hoogendijk JE, Hendrickx AT, de Coo IF, Doevendans PA, de Jong PT, Spliet WG, Kroes H, Smeets HJ. Additional mitochondrial DNA mutations may explain extra-ocular involvement in LHON. Am J Med Genet A. 2006 Jul 1;140(13):1478-81. doi: 10.1002/ajmg.a.31324. PMID: 16770803.
Puomila A, Hämäläinen P, Kivioja S, Savontaus ML, Koivumäki S, Huoponen K, Nikoskelainen E. Epidemiology and penetrance of Leber hereditary optic neuropathy in Finland. Eur J Hum Genet. 2007 Oct;15(10):1079-89. doi: 10.1038/sj.ejhg.5201828. Epub 2007 Apr 4. PMID: 17406640.
Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ 2nd, Nikoskelainen EK. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science. 1988 Dec 9;242(4884):1427-30. doi: 10.1126/science.3201231. PMID: 3201231.
Howell N, Bindoff LA, McCullough DA, Kubacka I, Poulton J, Mackey D, Taylor L, Turnbull DM. Leber hereditary optic neuropathy: identification of the same mitochondrial ND1 mutation in six pedigrees. Am J Hum Genet. 1991 Nov;49(5):939-50. PMID: 1928099; PMCID: PMC1683233.
Howell N, Kubacka I, Xu M, McCullough DA. Leber hereditary optic neuropathy: involvement of the mitochondrial ND1 gene and evidence for an intragenic suppressor mutation. Am J Hum Genet. 1991 May;48(5):935-42. PMID: 2018041; PMCID: PMC1683051.
Nikoskelainen E, Vilkki J, Huoponen K, Savontaus ML. Recent advances in Leber's hereditary optic neuroretinopathy. Eye (Lond). 1991;5 ( Pt 3):291-3. doi: 10.1038/eye.1991.45. PMID: 1955049.
Chinnery PF, Andrews RM, Turnbull DM, Howell NN. Leber hereditary optic neuropathy: Does heteroplasmy influence the inheritance and expression of the G11778A mitochondrial DNA mutation? Am J Med Genet. 2001 Jan 22;98(3):235-43. doi: 10.1002/1096-8628(20010122)98:3<235::aid-ajmg1086>3.0.co;2-o. PMID: 11169561.
Valentino ML, Barboni P, Ghelli A, Bucchi L, Rengo C, Achilli A, Torroni A, Lugaresi A, Lodi R, Barbiroli B, Dotti M, Federico A, Baruzzi A, Carelli V. The ND1 gene of complex I is a mutational hot spot for Leber's hereditary optic neuropathy. Ann Neurol. 2004 Nov;56(5):631-41. doi: 10.1002/ana.20236. PMID: 15505787.
Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies. Prog Retin Eye Res. 2011 Mar;30(2):81-114. doi: 10.1016/j.preteyeres.2010.11.002. Epub 2010 Nov 26. PMID: 21112411; PMCID: PMC3081075.
Amaral-Fernandes MS, Marcondes AM, do Amor Divino Miranda PM, Maciel-Guerra AT, Sartorato EL. Mutations for Leber hereditary optic neuropathy in patients with alcohol and tobacco optic neuropathy. Mol Vis. 2011;17:3175-9. Epub 2011 Dec 7. PMID: 22194643; PMCID: PMC3244475.
Cullom ME, Heher KL, Miller NR, Savino PJ, Johns DR. Leber's hereditary optic neuropathy masquerading as tobacco-alcohol amblyopia. Arch Ophthalmol. 1993 Nov;111(11):1482-5. doi: 10.1001/archopht.1993.01090110048021. PMID: 8240101.
Kirkman MA, Yu-Wai-Man P, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF, Klopstock T, Chinnery PF. Gene-environment interactions in Leber hereditary optic neuropathy. Brain. 2009;132(Pt 9):2317-26.
Maass J, Matthé E. Bilateral vision loss due to Leber's hereditary optic neuropathy after long-term alcohol, nicotine and drug abuse. Doc Ophthalmol. 2018 Apr;136(2):145-153. doi: 10.1007/s10633-018-9622-5. Epub 2018 Jan 25. PMID: 29372350.
Nowomiejska K, Kiszka A, Maciejewski R, Jünemann A, Rejdak R. Central scotoma in tobacco-alcohol toxic optic neuropathy measured with semi-automated kinetic perimetry. Cutan Ocul Toxicol. 2018 Dec;37(4):319-323. doi: 10.1080/15569527.2018.1459666. Epub 2018 Apr 24. PMID: 29688089.
Baj J, Forma A, Kobak J, Tyczyńska M, Dudek I, Maani A, Teresiński G, Buszewicz G, Januszewski J, Flieger J. Toxic and Nutritional Optic Neuropathies—An Updated Mini-Review. International Journal of Environmental Research and Public Health. 2022; 19(5):3092. https://doi.org/10.3390/ijerph19053092
Samanta SK, Fariduddin K, Mahapatra N, Bhunia J, Mondal P. Hooch blindness: a community study report on a few indoor patients of toxic optic neuropathy following consumption of adulterated alcohol in West Bengal. Nepal J Ophthalmol. 2012 Jan-Jun;4(1):162-4. doi: 10.3126/nepjoph.v4i1.5868. PMID: 22344014.
Chiotoroiu SM, Noaghi M, Stefaniu GI, Secureanu FA, Purcarea VL, Zemba M. Tobacco-alcohol optic neuropathy--clinical challenges in diagnosis. J Med Life. 2014;7(4):472-6.
Wang MY, Sadun AA. Drug-related mitochondrial optic neuropathies. J Neuroophthalmol. 2013 Jun;33(2):172-8. doi: 10.1097/WNO.0b013e3182901969. PMID: 23681241.
Grzybowski A, Holder GE. Tobacco optic neuropathy (TON) - the historical and present concept of the disease. Acta Ophthalmol. 2011 Aug;89(5):495-9. doi: 10.1111/j.1755-3768.2009.01853.x. Epub 2010 Mar 16. PMID: 20337605.
Kerrison JB, Miller NR, Hsu F, Beaty TH, Maumenee IH, Smith KH, Savino PJ, Stone EM, Newman NJ. A case-control study of tobacco and alcohol consumption in Leber hereditary optic neuropathy. Am J Ophthalmol. 2000 Dec;130(6):803-12. doi: 10.1016/s0002-9394(00)00603-6. PMID: 11124301.
Hayreh SS. Ischemic optic neuropathy. Prog Retin Eye Res. 2009 Jan;28(1):34-62. doi: 10.1016/j.preteyeres.2008.11.002. Epub 2008 Nov 27. PMID: 19063989.
Obuchowska I, Mariak Z. Neuropatia niedokrwienna nerwu wzrokowego. Patogeneza, obraz kliniczny, diagnostyka i leczenie [Ischemic optic neuropathy. Pathogenesis, clinical features, diagnostics and treatment]. Klin Oczna. 2006;108(4-6):238-42. Polish. PMID: 17020004.
Hayreh SS. Risk factors in AION. Ophthalmology. 2001 Oct;108(10):1717-8. doi: 10.1016/s0161-6420(01)00738-2. PMID: 11581036.
Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998 Apr;125(4):509-20. doi: 10.1016/s0002-9394(99)80192-5. PMID: 9559737.
Pahor A, Pahor D. Klinische Befunde bei Patienten mit nicht arteriitischer anteriorer ischämischer Optikusneuropathie (NAION) unter 50 Jahren [Clinical Findings in Patients with Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION) Under 50 Years of Age]. Klin Monbl Augenheilkd. 2016 Jan;233(1):66-71. German. doi: 10.1055/s-0041-104773. Epub 2015 Oct 13. PMID: 26460575.
Hayreh SS, Zimmerman B. Visual field abnormalities in nonarteritic anterior ischemic optic neuropathy: their pattern and prevalence at initial examination. Arch Ophthalmol. 2005 Nov;123(11):1554-62. doi: 10.1001/archopht.123.11.1554. PMID: 16286618.
Wilhelm H, Beisse F, Rüther K. Die nicht arteriitische anteriore ischämische Optikusneuropathie (NAION) [Non-Arteritic Ischemic Optic Neuropathy (NAION)]. Klin Monbl Augenheilkd. 2015 Nov;232(11):1260-9. German. doi: 10.1055/s-0035-1558170. Epub 2015 Nov 17. PMID: 26575534.
van Oterendorp C, Lagrèze WA, Feltgen N. Pathogenese und Therapie der nicht arteriitischen anterioren ischämischen Optikusneuropathie [Non-arteritic Anterior Ischaemic Optic Neuropathy: Pathogenesis and Therapeutic Approaches]. Klin Monbl Augenheilkd. 2019 Nov;236(11):1283-1291. German. doi: 10.1055/a-0972-1625. Epub 2019 Nov 11. PMID: 31711249.
Tesser RA, Niendorf ER, Levin LA. The morphology of an infarct in nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2003 Oct;110(10):2031-5. doi: 10.1016/S0161-6420(03)00804-2. PMID: 14522783.
Egan R. Prothrombotic and vascular risk factors in NAION. Ophthalmology. 2000 Dec;107(12):2116-7. doi: 10.1016/s0161-6420(00)00258-x. PMID: 11097559.
Salomon O, Huna-Baron R, Kurtz S, Steinberg DM, Moisseiev J, Rosenberg N, Yassur I, Vidne O, Zivelin A, Gitel S, Davidson J, Ravid B, Seligsohn U. Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 1999 Apr;106(4):739-42. doi: 10.1016/S0161-6420(99)90159-8. PMID: 10201595.
Reddy D, Rani PK, Jalali S, Rao HL. A study of prevalence and risk factors of diabetic retinopathy in patients with non-arteritic anterior ischemic optic neuropathy (NA-AION). Semin Ophthalmol. 2015 Mar;30(2):101-4. doi: 10.3109/08820538.2013.833262. Epub 2013 Oct 30. PMID: 24171808
Pahor D, Gracner B. Weitsichtigkeit als Risikofaktor für Patienten mit nicht arteritischer anteriorer ischämischer Optikusneuropathie [Hyperopia as a risk factor in patients with non-arteritic anterior ischaemic optic neuropathy]. Klin Monbl Augenheilkd. 2008 Dec;225(12):1070-4. German. doi: 10.1055/s-2008-1028000. Epub 2008 Dec 15. PMID: 19085788.
Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: clinical characteristics in diabetic patients versus nondiabetic patients. Ophthalmology. 2008 Oct;115(10):1818-25. doi: 10.1016/j.ophtha.2008.03.032. Epub 2008 May 27. PMID: 18502511.
Chang MY, Keltner JL. Risk Factors for Fellow Eye Involvement in Nonarteritic Anterior Ischemic Optic Neuropathy. J Neuroophthalmol. 2019 Jun;39(2):147-152. doi: 10.1097/WNO.0000000000000715. PMID: 30300257.
Fodor M, Nagy V, Berta A, Tornai I, Pfliegler G. Hepatitis C virus presumably associated bilateral consecutive anterior ischemic optic neuropathy. Eur J Ophthalmol. 2008 Mar-Apr;18(2):313-5. doi: 10.1177/112067210801800226. PMID: 18320531.
Sinnreich M, Rossillion B, Landis T, Burkhard PR, Sztajzel R. Bilateral optic ischemic neuropathy related to chronic hepatitis C-associated anticardiolipin antibodies. Eur Neurol. 2003;49(4):243-5. doi: 10.1159/000070195. PMID: 12736543.
Brazis PW, Spivey JR, Bolling JP, Steers JL. A case of bilateral optic neuropathy in a patient on tacrolimus (FK506) therapy after liver transplantation. Am J Ophthalmol. 2000 Apr;129(4):536-8. doi: 10.1016/s0002-9394(99)00443-2. PMID: 10764869.
Yaghi C, Baz P, Koussa S, Daniel F, Haddad F, Sayegh R. Neuropathie optique ischémique antérieure aiguë compliquant un traitement par interféron alpha-2a et ribavirine pour hépatite aiguë virale C [Ischemic anterior optic neuropathy complicating interferon alpha-2a and ribavirin treatment for acute hepatitis C]. Gastroenterol Clin Biol. 2005 May;29(5):616-7. French. doi: 10.1016/s0399-8320(05)82144-x. PMID: 15980766.
Gupta R, Singh S, Tang R, Blackwell TA, Schiffman JS. Anterior ischemic optic neuropathy caused by interferon alpha therapy. Am J Med. 2002 Jun 1;112(8):683-4. doi: 10.1016/s0002-9343(02)01102-6. PMID: 12034426.
Chun, B. Y., & Rizzo, J. F. (2017). Dominant Optic Atrophy and Leber’s Hereditary Optic Neuropathy: Update on Clinical Features and Current Therapeutic Approaches. Seminars in Pediatric Neurology, 24(2), 129–134.
Heitz FD, Erb M, Anklin C, Robay D, Pernet V, Gueven N. Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy. PLoS One. 2012;7(9):e45182.
Gueven N. Idebenone for Leber's hereditary optic neuropathy. Drugs Today (Barc). 2016 Mar;52(3):173-81.
Zhao, X., Zhang, Y., Lu, L., & Yang, H. (2020). Therapeutic Effects of Idebenone on Leber Hereditary Optic Neuropathy. Current Eye Research.
Jurkute, N., Harvey, J., & Yu-Wai-Man, P. (2018). Treatment strategies for Leber hereditary optic neuropathy. Current Opinion in Neurology, 1.
Catarino CB, von Livonius B, Priglinger C, Banik R, Matloob S, Tamhankar MA, Castillo L, Friedburg C, Halfpenny CA, Lincoln JA, Traber GL, Acaroglu G, Black GCM, Doncel C, Fraser CL, Jakubaszko J, Landau K, Langenegger SJ, Muñoz-Negrete FJ, Newman NJ, Poulton J, Scoppettuolo E, Subramanian P, Toosy AT, Vidal M, Vincent AL, Votruba M, Zarowski M, Zermansky A, Lob F, Rudolph G, Mikazans O, Silva M, Llòria X, Metz G, Klopstock T. Real-World Clinical Experience With Idebenone in the Treatment of Leber Hereditary Optic Neuropathy. J Neuroophthalmol. 2020 Dec;40(4):558-565.
Zuccarelli M, Vella-Szijj J, Serracino-Inglott A, Borg JJ. Treatment of Leber's hereditary optic neuropathy: An overview of recent developments. Eur J Ophthalmol. 2020 Nov;30(6):1220-1227.
Newman NJ, Yu-Wai-Man P, Carelli V, Moster ML, Biousse V, Vignal-Clermont C, Sergott RC, Klopstock T, Sadun AA, Barboni P, DeBusk AA, Girmens JF, Rudolph G, Karanjia R, Taiel M, Blouin L, Smits G, Katz B, Sahel JA; LHON Study Group. Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset. Ophthalmology. 2021 May;128(5):649-660.
Yu-Wai-Man P, Newman NJ, Carelli V, Moster ML, Biousse V, Sadun AA, Klopstock T, Vignal-Clermont C, Sergott RC, Rudolph G, La Morgia C, Karanjia R, Taiel M, Blouin L, Burguière P, Smits G, Chevalier C, Masonson H, Salermo Y, Katz B, Picaud S, Calkins DJ, Sahel JA. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci Transl Med. 2020 Dec 9;12(573):eaaz7423.
Newman NJ, Yu-Wai-Man P, Carelli V, Biousse V, Moster ML, Vignal-Clermont C, Sergott RC, Klopstock T, Sadun AA, Girmens JF, La Morgia C, DeBusk AA, Jurkute N, Priglinger C, Karanjia R, Josse C, Salzmann J, Montestruc F, Roux M, Taiel M, Sahel JA. Intravitreal Gene Therapy vs. Natural History in Patients With Leber Hereditary Optic Neuropathy Carrying the m.11778G>A ND4 Mutation: Systematic Review and Indirect Comparison. Front Neurol. 2021 May 24;12:662838.
Sadun AA, Chicani CF, Ross-Cisneros FN, Barboni P, Thoolen M, Shrader WD, Kubis K, Carelli V, Miller G. Efect of epi-743 on the clinical course of the mitochondrial disease leber hereditary optic neuropathy. Arch Neurol. 2012;69(3):331–8.
Rustum Karanjia SGC, Garcia M, Sadun AA. Elamipretide (mtp131) topical ophthalmic solution for the treatment of leber’s hereditary optic neuropathy. Investig Ophthalmol Visual Sci. 2019;60:2266.
Pisano A, Preziuso C, Iommarini L, Perli E, Grazioli P, Campese AF, Maresca A, Montopoli M, Masuelli L, Sadun AA, d’Amati G, et al. Targeting estrogen receptor beta as preventive therapeutic strategy for leber’s hereditary optic neuropathy. Hum Mol Genet. 2015;24(24):6921–31.
Yu AK, Datta S, McMackin MZ, Cortopassi GA. Rescue of cell death and infammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules. Hum Mol Genet. 2017;26(24):4929–36.
Weiss JN, Levy S, Benes SC. Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow-derived stem cells in the treatment of Leber's hereditary optic neuropathy. Neural Regen Res. 2016 Oct;11(10):1685-1694.
Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990 Aug;33(8):1122-8.
Bernstein SL, Johnson MA, Miller NR. Nonarteritic anterior ischemic optic neuropathy (NAION) and its experimental models. Progress in Retinal and eye Research. 2011 May;30(3):167-187.
Morrow MJ. Ischemic Optic Neuropathy. Continuum (Minneap Minn). 2019 Oct;25(5):1215-1235.
Hellmich B, Agueda A, Monti S, et al2018 Update of the EULAR recommendations for the management of large vessel vasculitisAnnals of the Rheumatic Diseases 2020;79:19-30.
Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology (Oxford). 2020 Mar 1;59(3):e1-e23.
Singh AG, Kermani TA, Crowson CS, Weyand CM,Matteson EL, Warrington KJ. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort.J Rheumatol. 2015;42:309-315
Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology. 2003 Jun;110(6):1204-15.
Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand. 2002 Aug;80(4):355-67.
Chan CC, Paine M, O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol. 2001;85(9):1061-1064.
González-Gay MA, Blanco R, Rodríguez-Valverde V, Martínez-Taboada VM, Delgado-Rodriguez M, Figueroa M, Uriarte E. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998 Aug;41(8):1497-504.
Patil P, Williams M, Maw WW, Achilleos K, Elsideeg S, Dejaco C, Borg F, Gupta S, Dasgupta B. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-103-6.
El Chami S, Springer JM. Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica. Med Clin North Am. 2021 Mar;105(2):311-324.
Sergott RC, Cohen MS, Bosley TM, Savino PJ. Optic Nerve Decompression May Improve the Progressive Form of Nonarteritic Ischemic Optic Neuropathy. Arch Ophthalmol. 1989;107(12):1743–1754.
Kelman SE, Elman MJ. Optic Nerve Sheath Decompression for Nonarteritic Ischemic Optic Neuropathy Improves Multiple Visual Function Measurements. Arch Ophthalmol. 1991;109(5):667–671.
Spoor TC, McHenry JG, Lau-Sickon L. Progressive and static nonarteritic ischemic optic neuropathy treated by optic nerve sheath decompression. Ophthalmology. 1993 Mar;100(3):306-11.
Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group. JAMA. 1995 Feb 22;273(8):625-32.
Egan, Robert A. ; Arnold, Anthony C. ; Lee, Andrew G. ; Van Stavern, Gregory P. / Should Aspirin Be Prescribed to Prevent Recurrence in Nonarteritic Anterior Ischemic Optic Neuropathy?. In: Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2020 ; Vol. 40, No. 3. pp. 428-433.
Kupersmith MJ, Frohman L, Sanderson M, Jacobs J, Hirschfeld J, Ku C, Warren FA. Aspirin reduces the incidence of second eye NAION: a retrospective study. J Neuroophthalmol. 1997 Dec;17(4):250-3.
Salomon O, Huna-Baron R, Steinberg DM, Kurtz S, Seligsohn U. Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. Eye (Lond). 1999 Jun;13 ( Pt 3a):357-9.
Beck RW, Hayreh SS, Podhajsky PA, Tan ES, Moke PS. Aspirin therapy in nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997 Feb;123(2):212-7.
Botelho PJ, Johnson LN, Arnold AC. The effect of aspirin on the visual outcome of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1996 Apr;121(4):450-1.
Newman NJ, Scherer R, Langenberg P, Kelman S, Feldon S, Kaufman D, Dickersin K; Ischemic Optic Neuropathy Decompression Trial Research Group. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol. 2002 Sep;134(3):317-28.
Hayreh SS. Ischemic optic neuropathies - where are we now? Graefes Arch Clin Exp Ophthalmol. 2013 Aug;251(8):1873-84.
Hayreh SS, Zimmerman MB. Optic disc edema in non-arteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol. 2007 Aug;245(8):1107-21.
Hayreh, S.S., Zimmerman, M.B. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 246, 1029–1046 (2008).
Atkins EJ, Bruce BB, Newman NJ, Biousse V. Treatment of nonarteritic anterior ischemic optic neuropathy. Surv Ophthalmol. 2010 Jan-Feb;55(1):47-63.
Rebolleda G, Pérez-López M, Casas-LLera P, Contreras I, Muñoz-Negrete FJ. Visual and anatomical outcomes of non-arteritic anterior ischemic optic neuropathy with high-dose systemic corticosteroids. Graefes Arch Clin Exp Ophthalmol. 2013 Jan;251(1):255-60.
Pakravan M, Sanjari N, Esfandiari H, Pakravan P, Yaseri M. The effect of high-dose steroids, and normobaric oxygen therapy, on recent onset non-arteritic anterior ischemic optic neuropathy: a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2016 Oct;254(10):2043-2048.
Durbant E, Radoi C, Garcia T, Denoyer A, Arndt C. Intravitreal triamcinolone injections in non-arteritic anterior ischemic optic neuropathy - A retrospective report. J Fr Ophtalmol. 2021 Jun;44(6):777-785.
Yaman A, Selver OB, Saatci AO, Soylev MF. Intravitreal triamcinolone acetonide injection for acute non-arteritic anterior ischaemic optic neuropathy. Clin Exp Optom. 2008 Nov;91(6):561-4.
Kaderli B, Avci R, Yucel A, Guler K, Gelisken O. Intravitreal triamcinolone improves recovery of visual acuity in nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2007 Sep;27(3):164-8.
Saxena R, Singh D, Sharma M, James M, Sharma P, Menon V. Steroids versus No Steroids in Nonarteritic Anterior Ischemic Optic Neuropathy: A Randomized Controlled Trial. Ophthalmology. 2018 Oct;125(10):1623-1627.
Chen J, Zhu J, Chen L, Hu C, Du Y. Steroids in the treatment of nonarteritic anterior ischemic optic neuropathy: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2019 Nov;98(46):e17861.
Wilhelm B, Lüdtke H, Wilhelm H; BRAION Study Group. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. Graefes Arch Clin Exp Ophthalmol. 2006 May;244(5):551-8.
Rootman DB, Gill HS, Margolin EA. Intravitreal bevacizumab for the treatment of nonarteritic anterior ischemic optic neuropathy: a prospective trial. Eye (Lond). 2013 Apr;27(4):538-44.
Modarres M, Falavarjani KG, Nazari H, et al Intravitreal erythropoietin injection for the treatment of non-arteritic anterior ischaemic optic neuropathyBritish Journal of Ophthalmology 2011;95:992-995.
Pakravan M, Esfandiari H, Hassanpour K, Razavi S, Pakravan P. The Effect of Combined Systemic Erythropoietin and Steroid on Non-arteritic Anterior Ischemic Optic Neuropathy: A Prospective Study. Curr Eye Res. 2017 Jul;42(7):1079-1084.
Lyttle DP, Johnson LN, Margolin EA, Madsen RW. Levodopa as a possible treatment of visual loss in nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol. 2016 Apr;254(4):757-64.
Johnson LN, Guy ME, Krohel GB, Madsen RW. Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2000 Mar;107(3):521-6.
Hayreh SS. Posterior ischemic optic neuropathy. Ophthalmologica. 1981;182(1):29-41.
Hayreh, SS. Posterior ischaemic optic neuropathy: clinical features, pathogenesis, and management. Eye 18, 1188–1206 (2004).
Sadda SR, Nee M, Miller NR, Biousse V, Newman NJ, Kouzis A. Clinical spectrum of posterior ischemic optic neuropathy. Am J Ophthalmol. 2001 Nov;132(5):743-50.
Athappilly G, Pelak VS, Mandava N, Bennett JL. Ischemic optic neuropathy. Neurol Res. 2008 Oct;30(8):794-800.
Wang MY, Brewer R, Sadun AA. Posterior ischemic optic neuropathy: Perioperative risk factors. Taiwan J Ophthalmol. 2020 Sep 11;10(3):167-173.
Patil CG, Lad EM, Lad SP, Ho C, Boakye M. Visual loss after spine surgery: a population-based study. Spine (Phila Pa 1976). 2008 Jun 1;33(13):1491-6.
Lee LA, Roth S, Posner KL, Cheney FW, Caplan RA, Newman NJ, Domino KB. The American Society of Anesthesiologists Postoperative Visual Loss Registry: analysis of 93 spine surgery cases with postoperative visual loss. Anesthesiology. 2006 Oct;105(4):652-9; quiz 867-8.
Fandino W. Strategies to prevent ischemic optic neuropathy following major spine surgery: A narrative review. J Clin Anesth. 2017 Dec;43:50-58.
Roda M, di Geronimo N, Pellegrini M, Schiavi C. Nutritional Optic Neuropathies: State of the Art and Emerging Evidences. Nutrients. 2020 Aug 31;12(9):2653.
Devalia V, Hamilton MS, Molloy AM; British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166(4):496–513.
Langan RC, Goodbred AJ. Vitamin B12 Deficiency: Recognition and Management. Am Fam Physician. 2017 Sep 15;96(6):384-389.
Hunt A, Harrington D, Robinson S. Vitamin B12 deficiency. BMJ. 2014;349g5226.
Rapoport Y, Lavin PJ. Nutritional Optic Neuropathy Caused by Copper Deficiency After Bariatric Surgery. J Neuroophthalmol. 2016 Jun;36(2):178-81.
Naismith RT, Shepherd JB, Weihl CC, Tutlam NT, Cross AH. Acute and bilateral blindness due to optic neuropathy associated with copper deficiency. Arch Neurol. 2009 Aug;66(8):1025-7.
Jefferis JM, Hickman SJ. Treatment and Outcomes in Nutritional Optic Neuropathy. Curr Treat Options Neurol. 2019 Feb 7;21(1):5
Sechi G, Serra A. Wernicke’s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442–455
Zamani N, Hassanian-Moghaddam H, Shojaei M, Rahimian S. Evaluation of the effect of erythropoietin + corticosteroid versus corticosteroid alone in methanol-induced optic nerve neuropathy. Cutan Ocul Toxicol. 2018 Jun;37(2):186-190.
Pakdel F, Sanjari MS, Naderi A, Pirmarzdashti N, Haghighi A, Kashkouli MB. Erythropoietin in Treatment of Methanol Optic Neuropathy. J Neuroophthalmol. 2018 Jun;38(2):167-171.
Pakravan M, Esfandiari H, Sanjari N, Ghahari E. Erythropoietin as an adjunctive treatment for methanol-induced toxic optic neuropathy. Am J Drug Alcohol Abuse. 2016;42(6):633-639.
Pakravan M, Sanjari N. Erythropoietin treatment for methanol optic neuropathy. J Neuroophthalmol. 2012;32(4):325-8.
Feizi, S., Alemzadeh-Ansari, M., Karimian, F., & Esfandiari, H. (2021). Use of erythropoietin in ophthalmology: a review. Survey of Ophthalmology.
Acar U, Kucuk B, Sevinc MK, Aykas S, Erdurmus M, Sobaci G. Intravitreal erythropoietin injection in late-stage optic neuropathy: a safety study on human. Int Ophthalmol. 2018 Jun;38(3):1021-1025.
Sadun AA, Wang MY. Ethambutol optic neuropathy: how we can prevent 100,000 new cases of blindness each year. J Neuroophthalmol. 2008 Dec;28(4):265-8.
Fraunfelder FW, Sadun AA, Wood T. Update on ethambutol optic neuropathy. Expert Opin Drug Saf. 2006 Sep;5(5):615-8.
Kanaujia V, Jain VK, Sharma K, Agarwal R, Mishra P, Sharma RK. Ethambutol-induced optic neuropathy in renal disorder: a clinico-electrophysiological study. Can J Ophthalmol. 2019 Jun;54(3):301-305.
Song W, Si S. The rare ethambutol-induced optic neuropathy: A case-report and literature review. Medicine (Baltimore). 2017 Jan;96(2):e5889.
Bouffard MA, Nathavitharana RR, Yassa DS, Torun N. Re-Treatment With Ethambutol After Toxic Optic Neuropathy. J Neuroophthalmol. 2017 Mar;37(1):40-42.
Lee EJ, Kim SJ, Choung HK, Kim JH, Yu YS. Incidence and clinical features of ethambutol-induced optic neuropathy in Korea. J Neuroophthalmol. 2008 Dec;28(4):269-77.
Tsai RK, Lee YH. Reversibility of ethambutol optic neuropathy. J Ocul Pharmacol Ther. 1997 Oct;13(5):473-7.
Addy LK, Harrison WW. Case Report: Long-term Structural and Functional Effects of Ethambutol Optic Neuropathy. Optom Vis Sci. 2020 Aug;97(8):555-560.
Chamberlain PD, Sadaka A, Berry S, Lee AG. Ethambutol optic neuropathy. Curr Opin Ophthalmol. 2017 Nov;28(6):545-551.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Joanna Kobak, Magdalena Tyczyńska, Alicja Forma, Iga Dudek, Amr Maani, Patryk Zembala, Jacek Baj
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 587
Number of citations: 0